New findings from the ERS Global Congress on Lung Diseases present a paradigm shift in COPD treatment: Early identification of type 2 inflammation and personalized biologic therapy.

Sanofi (($SNYNF)) announced an update on their ongoing clinical study. Sanofi is conducting a study titled ‘A Phase 2b/3, Randomized, ...

Among adults with COPD and type 2 inflammation, having a history of cardiovascular or metabolic disease did not change ...

Please provide your email address to receive an email when new articles are posted on . Data were derived from Baldomero AK, et al. JAMA Netw Open. 2025;doi:10.1001 ...

Inhaled corticosteroids pose long-term risks in COPD management, prompting careful screening and potential de-escalation ...

Expedition Therapeutics is gearing up for a phase 2 trek with a $165 million series A that closed Oct. 9. The new funding ...

The development could help scientists develop patient-specific treatments and one day offer a lab-grown lung transplant ...

The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organization (CDSCO) has recommended the grant of ...

"These emissions drive global warming, exacerbating the very respiratory conditions inhalers are meant to relieve," ...

Expedition Therapeutics Raises $165 Million in Oversubscribed Series A Financing to Advance Next-Generation DPP1 inhibitor ...